Canadian Biosimilars Body Calls For Expansion Of Switching
Other Provinces Urged To Emulate British Columbia And Alberta Programs
Further Canadian provinces should follow British Columbia and Alberta by adopting biosimilar switching programs, Biosimilars Canada has urged, in the wake of the latest expansion of the British Columbia program to cover adalimumab.
You may also be interested in...
New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.
British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.